Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

Online First

FDA Oncology Update

Omisirge FDA Approved for Patients with Hematologic Malignancies to Reduce Time to Neutrophil Recovery and Infection

Original Article

Retrospective Evaluation of Initial Empiric Double Coverage with Tobramycin in Adult Patients with Febrile Neutropenia

Original Article

Stopping Oral Chemotherapy Agents with a High Bleeding Risk Before and After Minor Surgical Procedures

FDA Oncology Update

Padcev plus Keytruda Granted Accelerated FDA Approval for Locally Advanced or Metastatic Urothelial Carcinoma

JHOP - April 2023 Vol 13, No 2

Original Article

Evaluation of Outcomes in Patients Who Received Bevacizumab for the Treatment of Brain Radionecrosis

Original Article

Incidence and Severity of Neuropathy with Concurrent Use of Voriconazole and Vincristine in Pediatric Patients with Cancer

Practical Issues in Pharmacy Management

Oral Chemotherapy Program Metrics: Results of a National Survey

Case Reports

Palbociclib-Induced Hepatotoxicity in a Patient with Metastatic Breast Cancer: A Case Report

Case Reports

Novel Use of Ravulizumab in Transplant-Associated Thrombotic Microangiopathy: Case Report

Original Article

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders: A Single-Center Experience

FDA Oncology Update

FDA Approved Zynyz for Metastatic or Recurrent Locally Advanced Merkel-Cell Carcinoma

FDA Approved Tafinlar plus Mekinist for Pediatric Patients with BRAF V600E Mutation–Positive Low-Grade Glioma

FDA Granted Jemperli Regular Approval for dMMR Endometrial Cancer

FDA Expanded Eligibility for Verzenio plus Endocrine Therapy in Patients with Early Breast Cancer

Trodelvy Now FDA Approved for HR-Positive, HER2-Negative Breast Cancer

Orserdu FDA Approved for ER-Positive Advanced or Metastatic Breast Cancer with ESR1 Mutation

Most Popular Articles

JHOP - December 2022 Vol 12, No 6 - Review Article

Pancreatic Cancer: Review of the Current and Investigational Drug Landscape

JHOP - February 2023 Vol 13, No 1 - Original Article

Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego

JHOP - December 2022 Vol 12, No 6 - Case Reports

Neoadjuvant FOLFIRINOX Therapy for a Patient with Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Hemodialysis: Case Report

JHOP - December 2022 Vol 12, No 6 - Original Article

Incidence of Hypothyroidism in Patients with Cancer Receiving Immune Checkpoint Inhibitors

JHOP - February 2023 Vol 13, No 1 - Original Article

Comparing the Efficacy and Safety of Reference Drug Filgrastim and Biosimilar Filgrastim-sndz in Pediatric Patients Used for Post–Hematopoietic Stem-Cell Transplant Engraftment or Chemotherapy-Induced Febrile Neutropenia Prophylaxis

JHOP - April 2023 Vol 13, No 2 - Practical Issues in Pharmacy Management

Oral Chemotherapy Program Metrics: Results of a National Survey